The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure - Full Text View

The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure (REMODEL)

This study has been completed.

First Received: May 12, 2004 Last Updated: May 22, 2008 History of Changes

Sponsored by:	Pfizer
Information provided by:	Pfizer
ClinicalTrials.gov Identifier:	NCT00082589

Purpose

The purpose of this study is to determine if eplerenone is effective in the treatment of mild to moderate heart failure

Condition	Intervention	Phase
Heart Failure, Congestive	Drug: Eplerenone	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study
Official Title:	A Randomized, Double-Blind, Multi-Center,Study Evaluating the Effects of Eplerenone Versus Placebo on Ventricular Remodeling in Patient's With Left Ventricular Systolic Dysfunction (EF Less Than or Equal to 35%) and Mild to Moderate Heart Failure

Resource links provided by NLM:

MedlinePlus related topics: Heart Failure

Further study details as provided by Pfizer:

Primary Outcome Measures:

Difference between eplerenone and placebo in change from baseline in LV end diastolic volume index (EDVi) determined by equilibrium-gated radionuclide ventriculography (RVG)

Estimated Enrollment:	250
Study Start Date:	April 2004
Estimated Study Completion Date:	March 2006

Eligibility

Criteria

Inclusion Criteria:

Current symptoms consistent with mild to moderate heart failure (NYHA functional class II and III)
LVEF (left ventricular ejection fraction) of <35% by equilibrium-gated RVG at screening
Therapy with an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) and beta-blocker (BB) (unless documented intolerance) for at least 3 months duration and at dose that has not been adjusted within the previous 4 weeks

Exclusion Criteria:

Current decompensated heart failure or heart failure hospitalization or severe heart failure (NYHA functional class IV) within 6 months of screening
Use of eplerenone or spironolactone within 30 days of randomization or for more than 7 days within the previous 6 months

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00082589

Sponsors and Collaborators

Pfizer

Investigators

Study Director:

Pfizer CT.gov Call Center

Pfizer

More Information

Additional Information:

Link to ClinicalStudyResults.org Posting: This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	A6141078
Study First Received:	May 12, 2004
Last Updated:	May 22, 2008
ClinicalTrials.gov Identifier:	NCT00082589 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Eplerenone
Heart Failure
Heart Diseases
Aldosterone Antagonists

Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Hormones

Additional relevant MeSH terms:

Eplerenone
Heart Failure
Heart Diseases
Aldosterone Antagonists
Hormone Antagonists

Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Cardiovascular Diseases
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 02, 2009